The medical insurance negotiations entered the second day and these varieties were passed!

The health care negotiation is still in intense progress A number of varieties have been negotiated, and the dawn is ahead On November 12, the second day of the health insurance negotiation, the tense atmosphere did not abate, and many pharmaceutical enterprises were still waiting anxiously at the negotiation site of West Chang'an Street in Beijing (photo source: sapphire blue) For 70 companies of the products to be negotiated and 31 companies of the products to be renewed, the health insurance negotiation is a big test, which directly determines the sales volume and patient accessibility of the products of the future enterprises, and the negotiation result is the final test result Sabilan learned outside the negotiation site that the process of on-site negotiation is mainly to carry out on-site negotiation between the medical insurance party and the enterprise, determine the negotiation results after leaving the site, and carry out the negotiation in several groups The negotiation group randomly selects the negotiation varieties In principle, the competitive products are negotiated in one group, each of which has 30 minutes and two price opportunities Different from yesterday, today's enterprises that come out after the negotiation are secretive about the final results, but some people are happy and some are worried From the response of the corresponding pharmaceutical enterprises, we can have a glimpse of the final results Sepiland learned at the scene that Bayer's related products are more likely to enter the medical insurance It is reported that among the 21 negotiated varieties of medical insurance in 2019, Bayer's sorafenib oral regular release dosage form entered the medical insurance in 2017, with the payment standard of 203 yuan (0.2g / tablet) After two years, the negotiation will be held again How about the decline? It can wait for the subsequent official announcement According to insight database, there are 31 varieties to be negotiated after 2017, including 276 approval numbers, involving 30 pharmaceutical enterprises And Bayer is not the only company that continues to negotiate According to the Jiangsu pharmaceutical alliance, there were 5 groups and 50 varieties discussed yesterday At present, the price of nisin microspheres of Sansheng has been reduced by 5%, the price of compound Huangdai tablets of Yifan pharmaceutical has been reduced by about 5%; the price of lilaluptide has been reduced by 10%, and the price of novobin in Tibet pharmaceutical industry has also been reduced by about 5% Roche also started the negotiation this afternoon Its products trastuzumab, bevacizumab and erlotinib are on the list of 31 varieties for further negotiation As a result, Roche's representatives are relaxed and take photos at the entrance of the conference hall with smiles on their faces Their products are also likely to be successful in the negotiation Previously, a group of data from iqvia showed that the growth rate of sales of drugs successfully included in the national health insurance catalog increased by 20 percentage points, but because the average price reduction reached 40%, the growth rate of sales only increased by 3 percentage points In addition, only when the sales volume growth drives the sales volume growth can we make up for the impact of the sharp price reduction, which will take a certain period of time For those varieties that have entered the medical insurance through negotiation in 2017, only after careful calculation and acceptance of a certain reduction, and entering the 2019 medical insurance catalog, can they obtain further sales growth However, according to the above known information, there is no substantial price reduction in this continuing negotiation, which shows that the price maintenance of these products is relatively successful It is worth mentioning that xiumeile, the global medicine king, has been in China for many years and finally achieved his long cherished wish to enter the medical insurance According to the eight o'clock news, Abbey's xiumeile finally negotiated successfully yesterday During this period, xiumeile reduced its price by nearly 60% nationwide, from 7608.38 yuan to 3160 yuan, which is widely considered by the industry as preparation for entering the medical insurance industry From 2012 to now, Sumeria has won the first place in global prescription drug sales for seven consecutive years In 2018, Sumeria was still defending the title with us $19.9 billion, nearly US $11 billion more than the second apixaban But such brilliant achievements are close to failure in China According to the data of minenet, in 2017, the sales volume of xiumeile, the terminal of public medical institutions in China, was 81.25 million yuan, because xiumeile did not enter the national medical insurance, and it was mainly self paid patients In order to show his sincerity in entering the medical insurance, Sumeria will reduce one to 3160 yuan Based on the dosage of two weeks, the cost of one month is 6320 yuan, which is significantly reduced compared with 15200 yuan / month in the past Compared with the similar drug golimub, the price is 5000 yuan / month, and then through the medical insurance negotiation, the price can be kept at the same level In the end, Abbott's xiumeile did enter the medical insurance shortly after the domestic "xiumeile" went on the market and got the long cherished wish In addition, sepiland also learned at the scene that the negotiation between androtinib in Zhengda Tianqing and aimelazole in Lizhu group was probably successful In May 2018, Zhengda Tianqing androtinib was officially approved by the National Drug Administration (nmpa) for the treatment of locally advanced or metastatic non-small cell lung cancer patients with progression or recurrence after receiving at least two kinds of systematic chemotherapy in the past There are opinions in the industry that the research and development of androtinib is an important step for "king of first imitation" to step out of the comfortable circle of generic drugs, and it is also the first innovative small molecule drug developed by the company according to the international research and development process and standards Its re-entry into the medical insurance will also promote the continuous volume of the innovative drug As far as the eimeridazole of Lizhu group is concerned, it has obvious advantages compared with the previous gastric drugs First, it has stronger activity of inhibiting gastric acid, and the same level of good drug effect is 4 quilt higher; second, it has no individual difference for different metabolic patients; third, it has fewer side effects According to eight Jianwen news, the price reduction of delamani tablet of Otsuka Pharmaceutical Co., Ltd is about 40%; the price reduction of Astragalus Polysaccharide for injection, a new class II traditional Chinese medicine product of Tianjin sanuo Pharmaceutical Co., Ltd is about 28%; the Compound Glycyrrhizin for injection of Sihuan Pharmaceutical Co., Ltd is also successfully negotiated at the same time There are already a number of varieties, and the health insurance negotiation has been passed (the current information is summarized above, all subject to the official final news.) According to iqvia data, medical insurance has a significant impact on the regional volume of products After being included in the national medical insurance catalog, the growth rate of drugs successfully negotiated in the third and second level hospitals is similar However, the overall growth rate of secondary hospitals is about 10% higher than that of tertiary hospitals It is worth noting that compared with first tier cities, patients in low tier cities have higher price sensitivity For example, after entering the medical insurance, the sales volume of the fourth tier cities in the first quarter of 2018 grew the most strongly, reaching 42%, and the growth rate reached 35% Therefore, the sales growth rate of the first tier cities is only half of that of the fourth tier cities, and the growth rate is the smallest, only 19 percentage points It can be seen from the above that the clinical application of drugs successfully included in the national medical insurance catalogue has been expanded and more hospitals have been entered After entering the medical insurance, enterprises can maximize the sales growth of successful drugs by ensuring the coverage and access of tertiary hospitals in all cities Health care negotiations are still under way, and the dawn is ahead The list of negotiated drugs during the agreement period is attached as follows: